These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 34831090)

  • 21. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.
    Bell SC; De Boeck K; Amaral MD
    Pharmacol Ther; 2015 Jan; 145():19-34. PubMed ID: 24932877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
    Cuyx S; De Boeck K
    Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological therapy for cystic fibrosis: from bench to bedside.
    Becq F; Mall MA; Sheppard DN; Conese M; Zegarra-Moran O
    J Cyst Fibros; 2011 Jun; 10 Suppl 2():S129-45. PubMed ID: 21658632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The chloride channel CFTR is not required for cyst growth in an ADPKD mouse model.
    Talbi K; Cabrita I; Kraus A; Hofmann S; Skoczynski K; Kunzelmann K; Buchholz B; Schreiber R
    FASEB J; 2021 Oct; 35(10):e21897. PubMed ID: 34473378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generation of two TMEM16A knockout iPSC clones each from a healthy human iPSC line, from a Cystic Fibrosis patient specific line with p.Phe508del mutation and from the gene corrected iPSC line.
    Jaboreck MC; Lühmann JL; Mielenz M; Stanke F; Göhring G; Martin U; Olmer R; Merkert S
    Stem Cell Res; 2022 Oct; 64():102918. PubMed ID: 36162332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence.
    Kotha K; Clancy JP
    Ther Adv Respir Dis; 2013 Oct; 7(5):288-96. PubMed ID: 24004658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Anion Channel TMEM16a/Ano1 Modulates CFTR Activity, but Does Not Function as an Apical Anion Channel in Colonic Epithelium from Cystic Fibrosis Patients and Healthy Individuals.
    Salari A; Xiu R; Amiri M; Pallenberg ST; Schreiber R; Dittrich AM; Tümmler B; Kunzelmann K; Seidler U
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762516
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Ca
    Liu Y; Liu Z; Wang K
    Acta Pharm Sin B; 2021 Jun; 11(6):1412-1433. PubMed ID: 34221860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cystic fibrosis: Physiopathology and the latest pharmacological treatments.
    Fonseca C; Bicker J; Alves G; Falcão A; Fortuna A
    Pharmacol Res; 2020 Dec; 162():105267. PubMed ID: 33127556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TMEM16A Mediates Mucus Production in Human Airway Epithelial Cells.
    Cabrita I; Benedetto R; Wanitchakool P; Lerias J; Centeio R; Ousingsawat J; Schreiber R; Kunzelmann K
    Am J Respir Cell Mol Biol; 2021 Jan; 64(1):50-58. PubMed ID: 33026825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toward inclusive therapy with CFTR modulators: Progress and challenges.
    Guimbellot J; Sharma J; Rowe SM
    Pediatr Pulmonol; 2017 Nov; 52(S48):S4-S14. PubMed ID: 28881097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
    Solomon GM; Marshall SG; Ramsey BW; Rowe SM
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cystic fibrosis transmembrane regulator correctors and potentiators.
    Rowe SM; Verkman AS
    Cold Spring Harb Perspect Med; 2013 Jul; 3(7):. PubMed ID: 23818513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Corrector combination therapies for F508del-CFTR.
    Hanrahan JW; Matthes E; Carlile G; Thomas DY
    Curr Opin Pharmacol; 2017 Jun; 34():105-111. PubMed ID: 29080476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unmet needs in cystic fibrosis.
    Rubin BK
    Expert Opin Biol Ther; 2018 Jul; 18(sup1):49-52. PubMed ID: 30063865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacogenetics of cystic fibrosis treatment.
    Carter SC; McKone EF
    Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CFTR: a hub for kinases and crosstalk of cAMP and Ca2+.
    Kunzelmann K; Mehta A
    FEBS J; 2013 Sep; 280(18):4417-29. PubMed ID: 23895508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.